Elevated Expression of <i>LYPD3</i> Is Associated with Lung Adenocarcinoma Carcinogenesis and Poor Prognosis

Abstract

Aberrant expression of <i>LYPD3</i> plays an oncogenic role in several types of cancer. However, the functions of <i>LYPD3</i> in lung adenocarcinoma (LUAD) remain unclear. Here, we investigated the regulatory function, clinical value, and prognostic significance of <i>LYPD3</i> in LUAD patients. The gene expression and DNA methylation data of LUAD tumor and paracancerous tissues were obtained from The Cancer Genome Atlas (TCGA) database. The association between <i>LYPD3</i> expression and clinicopathological variables was analyzed. The results showed that <i>LYPD3</i> was highly expressed in LUAD tumor compared with paracancerous tissues, which was positively correlated with the race (<i>p</i> = 0.0448), tumor stage (<i>p</i> = 0.0191), and survival status (<i>p</i> < 0.001). Furthermore, the expression of <i>LYPD3</i> was able to be regulated by the methylation in <i>LYPD3</i> promoter region, which was positively associated with the overall survival. Furthermore, we explored the related pathways through which <i>LYPD3</i> affects the pathogenesis and prognosis of LUAD by gene set enrichment analysis, and found that <i>LYPD3</i> might affect the clinical manifestations of LUAD by regulating the P53 signaling pathway. In the future, we would focus on exploring the molecular mechanism of <i>LYPD3</i> in the regulation of the occurrence and development of LUAD to provide a research basis for the screening of methylation markers related to the treatment and prognosis.